Pay in 4 interest-free payments of $5.09 Learn more
Ships within 48 hours · Estimated delivery Sep 3 - Sep 8
When appetite does hit, reaching for whatever's convenientoften not GLP-1-friendly options
Subcutaneous (often abbreviated as Sub-Q or SC) injection means delivering the compound into the layer of fat directly beneath the skin
Saxenda (Liraglutide) FDA approval: 2014 for chronic weight management Indicated population: Adults with BMI 30, OR Adults with BMI 27 with at least one weight-related condition Also available as: Victoza (lower dose, approved for Type 2 diabetes) Ozempic (Semaglutide) FDA approval: 2017 for Type 2 diabetes Indicated population: Adults with Type 2 diabetes as adjunct to diet and exercise Not approved for: Weight loss (though commonly prescribed off-label) Wegovy (Semaglutide) FDA approval: 2021 for chronic weight management Indicated population: Adults with BMI 30, OR Adults with BMI 27 with at least one weight-related condition Adolescents aged 12+ with obesity Same medication as Ozempic: Different dosing and FDA indication Practical Implications The regulatory distinctions matter for: Insurance coverage: Medications are often covered only for their approved indications
Smits MM, Tonneijck L, Muskiet MH, Hoekstra T, Kramer MH, Diamant M, et al
Some more common side effects reported have been nausea, diarrhea, and appetite suppression
